Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.4752W HIGH $12.58
Volume
20.79 K
Value Traded
59.74 K
Short % Float
13.9%
0%Week
+0.45%1 Month
-0.99%3 Month
+5.88%6 Month
-96.07%5 Year
-96.07%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
59.29 M
EPS (TTM)
-3.32
P/E Ratio
-
Ent. Value
-76.75 M
Total Shares
6.58 M
Float Shares
2.97 M
Insiders
54.88%
Institutions
27.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
XLO Catalyst Timeline
Dated clinical, regulatory and corporate events for Xilio Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Xilio Therapeutics, Inc.
282Total events
20Upcoming
56Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Yariv J. Houvras appointed Chief Medical Officer of Xilio Therapeutics
◆IND SubmissionIND
IND application anticipated for PSMA+STEAP1 T cell engager program
PSMA+STEAP1source ↗
◆Equity OfferingCorporate
Series C warrants exercisable for cash at $0.75 per share, potential $50M additional gross proceeds
◆Poster PresentationXTX601Presentation
Poster presentation of preclinical data for masked CLDN18.2-targeting T cell engager XTX601 at AACR 2026
cancersource ↗
◆Poster PresentationCLDN18Presentation
Poster presentation at AACR for CLDN18.2 program
gastrointestinal cancers, lung cancersource ↗
◆Development Candidate NominationPreclinical
Development candidate nomination for PSMA/STEAP1 program
prostate cancersource ↗
●Poster PresentationXTX601Presentation
Preclinical data for XTX601 presented at AACR
gastrointestinal cancerssource ↗
◆IND Enabling CompletePSMAPreclinical
IND-enabling activities for PSMA+STEAP1 program anticipated in Q2 2026
prostate cancersource ↗
▲Milestone PaymentCorporate
Achieved $6.0 million development milestone under AbbVie collaboration in Q2 2026
◆IND Enabling CompletePSMAPreclinical
IND-enabling activities initiation for PSMA+STEAP1 program
prostate cancersource ↗
◆Oral PresentationPresentation
Fireside chat at Leerink Partners Global Healthcare Conference
▼Equity OfferingCorporate
Pricing of underwritten offering of pre-funded warrants to purchase 74,780,300 shares at $0.5349 per warrant
▲Milestone PaymentCorporate
Achieved development milestone for masked antibody-based program under AbbVie agreement
●Development Candidate NominationCLDN18Preclinical
Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2
cancersource ↗
▼Equity OfferingCorporate
Received $35.8 million in gross proceeds from Series B warrant exercises
▲Milestone PaymentCorporate
Development milestone achieved under AbbVie collaboration in January 2026
●IND Enabling CompleteXTX601Preclinical
IND-enabling activities initiated for CLDN18.2 program
gastrointestinal cancers (gastric, pancreatic, esophageal)source ↗
◆Topline ReadoutvilastobartClinical Data
Additional data from Phase 2 trial expected, including 150 mg Q6W dose level data
metastatic microsatellite stable colorectal cancersource ↗
●Development Candidate NominationPreclinical
Nominate development candidate for STEAP1 masked T cell engager
Prostate, Lung, Colorectalsource ↗
◆Development Candidate NominationPreclinical
Development candidate nomination for STEAP1 program in SEECR format
prostate, colorectal, lung cancerssource ↗
●Quarterly UpdateCorporate
Estimated cash and cash equivalents of $137.5 million as of Dec 31, 2025; cash runway into Q2 2027
▲Oral PresentationvilastobartPresentation
Late-breaking Phase 2 data for vilastobart at SITC 2025
MSS mCRC without liver metastases, high plasma TMBsource ↗
▲Oral PresentationXTX301Presentation
Phase 1 data for efarindodekin alfa at SITC 2025
advanced solid tumorssource ↗
▲Poster PresentationPresentation
Preclinical data for masked T cell engager programs at SITC 2025
◆Quarterly UpdateCorporate
Conference call and webcast to discuss Phase 2 data for vilastobart with expert clinicians
◆Late-BreakervilastobartPresentation
Late-breaking poster presentation of Phase 2 data for vilastobart in combination with atezolizumab in MSS mCRC patients with high plasma tumor mutational burden at SITC 40th Annual Meeting
microsatellite stable metastatic colorectal cancersource ↗
▲Poster PresentationvilastobartPresentation
Late-breaking poster presentation of Phase 2 data for vilastobart in combination with atezolizumab in MSS mCRC at SITC 40th Annual Meeting
MSS metastatic colorectal cancersource ↗
▲Topline ReadoutvilastobartClinical Data
Phase 2 data: 40% ORR in heavily pre-treated MSS mCRC without liver metastases and high plasma TMB
MSS metastatic colorectal cancer without liver metastases and high plasma TMBsource ↗
▲Enrollment CompleteXTX301Trial
Enrollment completed in Phase 1A monotherapy dose escalation and Phase 1B monotherapy dose expansion
advanced solid tumorssource ↗
◆Poster PresentationvilastobartPresentation
Poster presentation of clinical data for vilastobart at SITC 2025
cancersource ↗
◆Poster PresentationXTX301Presentation
Poster presentation of clinical data for efarindodekin alfa at SITC 2025
cancersource ↗
◆Poster PresentationPresentation
Poster presentation of preclinical data for masked T cell engager programs at SITC 2025
cancersource ↗
●Poster PresentationvilastobartPresentation
Late-breaking poster presentation on ctDNA as early biomarker for vilastobart combination
MSS mCRCsource ↗
◆Equity OfferingCorporate
Series B warrants exercisable for cash at $0.75 per share, potential $50M additional gross proceeds
◆Development Candidate NominationCLDN18Preclinical
Anticipated development candidate nomination for CLDN18.2 ATACR program
gastric, pancreatic, esophageal, lung cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How XLO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | XTX501 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$50M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
0.9x
rNPV / MCap
Top 58%
Micro Cap(rank 382 of 658)
Percentile Rank
Xilio Therapeutics, Inc. faces pipeline headwinds (34/100), with $1.1B risk-adjusted pipeline value, led by XTX501 in Metastatic NSCLC - Non-Small Cell Lung Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| XTX501 Small moleculeNCT07688577 | Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 1 | NOT YET_RECRUITING | 140 | Nov 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every XLO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vilastobart | MSS metastatic colorectal cancer (mCRC) | Phase 2 | 2025-11-13 | In a late-breaking Phase 2 trial, vilastobart demonstrated a 40% overall response rate (ORR) in heavily pretreated patients with microsatellite stable metastatic colorectal cancer (mCRC) without liver metastases, highlighting its potential as a combination therapy.Read More | Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial ResultsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Blanchard Cheryl RDirector | Grant/Award | 10,000 10,000 held | $0.00 | 04/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XLO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 0.4 % (-20 %) | 6.36 M | 664.02 K |
XLO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XLO ranks across every disease it competes in
Competitive Position is a premium feature
See how XLO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXLO News
XLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics announced the granting of stock options to new employees as part of its 2022 Inducement Stock Incentive Plan. The grants include options for 100,895 shares to two new hires and 105,000 shares to the newly appointed Chief Medical Officer. The options have a ten-year term and will vest over time, contingent on continued employment.
Read more →XLOXilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Xilio Therapeutics has appointed Dr. Yariv Houvras as Chief Medical Officer. Dr. Houvras brings over 20 years of experience in clinical development and has a strong background in immuno-oncology. His leadership is expected to advance Xilio's pipeline, particularly the bispecific PD-1 / masked IL-2 therapy, XTX501. The company aims to improve cancer treatment outcomes while minimizing side effects.
Read more →XLOXilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics has reported its financial results for the second quarter of 2026, highlighting significant advancements in its pipeline. The company received FDA clearance for its IND application for XTX501, a bispecific PD-1 / masked IL-2 therapy. Additionally, Xilio is progressing with IND-enabling studies for multi-specific T cell engager programs targeting CLDN18.2 and PSMA+STEAP1.
Read more →XLOXilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Xilio Therapeutics has appointed Ben Harshbarger as its new Chief Legal Officer. Harshbarger, who has over 20 years of experience in the biopharmaceutical industry, will support the company's strategic goals as it advances its pipeline of immuno-oncology therapies. His previous roles include leadership positions at Astria Therapeutics and Novelion Therapeutics.
Read more →XLOXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics reported financial results for Q1 2026 and provided pipeline updates, indicating strong momentum in its development programs. The company is on track to submit an IND application for its bispecific PD-1/masked IL-2 therapy XTX501 by mid-2026 and aims to initiate the Phase 1 trial later that year. Notably, Xilio presented promising preclinical data for its XTX601 program at the AACR Annual Meeting. The company also reported a cash position of $150.3 million as of March 31, 2026, which, along with recent milestones, positions it well for continued development.
Read more →XLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7, 2026
Xilio Therapeutics announced the grant of stock options to a new employee as part of its 2022 Inducement Stock Incentive Plan. The options, totaling 1,982 shares, have an exercise price of $8.32 and will vest over a ten-year term. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent.
Read more →XLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics has granted non-qualified stock options to a new employee as part of its 2022 Inducement Stock Incentive Plan. The options, totaling 1,982 shares, have an exercise price of $8.32 per share and will vest over a period of time. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent.
Read more →XLOXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Xilio Therapeutics has announced promising preclinical data for its masked T cell engager XTX601, targeting the CLDN18.2 antigen, at the AACR Annual Meeting. The data shows that XTX601 exhibits potent anti-tumor activity and is well tolerated in non-human primates, suggesting a favorable therapeutic index. The innovative design aims to minimize systemic toxicity while effectively engaging T cells against solid tumors. Xilio plans to advance XTX601 to IND-enabling studies with an IND application anticipated in 2027.
Read more →XLOXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
Xilio Therapeutics has appointed Cheryl R. Blanchard, Ph.D., to its board of directors, enhancing its leadership team. Blanchard, with over three decades of experience in life sciences, is expected to contribute significantly to the development of Xilio's masked immuno-oncology therapies. Christina Rossi has stepped down from the board, marking a leadership transition.
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Xilio Therapeutics has announced significant progress in its pipeline, including the upcoming IND submission for XTX501, a bispecific PD-1 / masked IL-2 therapy, planned for mid-2026. The company is also advancing a multi-specific masked T cell engager targeting PSMA and STEAP1, with preclinical data presentation scheduled for the AACR Annual Meeting in April 2026. Xilio's financial results show a strong cash position, extending its runway through the end of 2027.
Read more →XLOXilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
Xilio Therapeutics announced a poster presentation at the AACR Annual Meeting, showcasing new preclinical data for its masked T cell engager program targeting CLDN18.2. The presentation is scheduled for April 20, 2026, and aims to highlight advancements in immuno-oncology therapies designed to improve cancer treatment outcomes. The company emphasizes its commitment to minimizing systemic side effects.
Read more →XLO▼ -5.3%on this newsshared move
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
Xilio Therapeutics announced a 1-for-14 reverse stock split effective March 13, 2026, to boost its stock price and comply with Nasdaq listing requirements. The split, approved by shareholders, will reduce the number of outstanding shares from approximately 73.5 million to about 5.2 million. Trading on a split-adjusted basis will commence on March 16, 2026.
Read more →XLOUnlocking the Potential of Immuno-Oncology Therapies
Xilio Therapeutics is advancing its pipeline of immuno-oncology therapies leveraging clinically-validated masking technology. The company focuses on developing tumor-selective therapies that aim to maximize anti-tumor activity while minimizing severe side effects. Xilio reports promising clinical data with durable responses across various tumor types and maintains collaborations with key industry partners like AbbVie and Gilead. However, the company faces potential risks related to clinical trial timelines and other operational factors that could affect its development goals.
Read more →XLOXilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Xilio Therapeutics announced its participation in the upcoming Leerink Partners Global Healthcare Conference, scheduled for March 9, 2026. The company's management will engage in a fireside chat, which will be accessible via a live webcast. Xilio is dedicated to developing masked immuno-oncology therapies aimed at improving cancer treatment outcomes.
Read more →XLO▲ +11.4%on this news
Xilio Therapeutics Announces Pricing of Underwritten Offering
Xilio Therapeutics announced the pricing of an underwritten offering of pre-funded warrants to purchase 74,780,300 shares of common stock at $0.5349 each. The offering is expected to close on February 13, 2026, and aims to raise around $40 million for product development and general corporate purposes. The financing was led by Coastlands Capital and included participation from several institutional investors.
Read more →About Xilio Therapeutics, Inc.
Headquarters828 WINTER STREET, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE PLUS
Trade the next XLO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime